Gonul Ozay
Neurology · Washington, DCNPI 1538884184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,648 and has fallen 70.8% since, to $1,357 in 2025.
Across 267 payments — averaging $27.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$1K
- AbbVie$905
- Acadia Pharmaceuticals Inc$742
- Merz Pharmaceuticals, LLC$629
- Amneal Pharmaceuticals LLC$625
- Teva Pharmaceuticals USA, Inc.$559
- plus $3K from 12 others
What the payments were for
- Food & beverage$7,18198%
- Education$1792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 11 | $1,349 |
| AbbVie | 48 | $905 |
| Acadia Pharmaceuticals Inc | 45 | $742 |
| Merz Pharmaceuticals, LLC | 19 | $629 |
| Amneal Pharmaceuticals LLC | 38 | $625 |
| Teva Pharmaceuticals USA, Inc. | 20 | $559 |
| Abbott | 11 | $503 |
| Neurocrine Biosciences, Inc. | 16 | $414 |
| Medtronic | 5 | $401 |
| Kyowa Kirin, Inc. | 18 | $329 |
| Revance Therapeutics, Inc. | 3 | $308 |
| Acorda Therapeutics, Inc | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 7 | $131 |
| Eisai Inc. | 7 | $118 |
| Lilly USA, LLC | 4 | $76 |
| Lundbeck LLC | 3 | $64 |
| Corium, LLC | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GOCOVRI$776
- INFINITY$327
- DAXXIFY$150
- PERCEPT PC BRAINSENSE$131
- Duopa$116
How this compares
$7,361 in reported general payments places this provider in the 65th percentile of 113 neurology providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 142 | $1,042,772 |
| RytaryCarbidopa/Levodopa | 307 | $435,496 |
| NourianzIstradefylline | 129 | $407,190 |
| GocovriAmantadine Hcl | 52 | $273,659 |
| Austedo XrDeutetrabenazine | 12 | $67,236 |
| Droxidopa | 35 | $65,378 |
| Rivastigmine | 169 | $52,797 |
| InbrijaLevodopa | 13 | $48,716 |
| Rasagiline Mesylate | 151 | $35,246 |
| Memantine Hcl ErMemantine Hcl | 17 | $4,084 |
| Memantine Hcl | 48 | $3,147 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 82 | $2,655 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 12 | $2,615 |
| Escitalopram Oxalate | 84 | $1,811 |
| Ropinirole ErRopinirole Hcl | 12 | $1,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $742 | $1,042,772142 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $625 | $436,415327 claims |
| Kyowa Kirin, Inc.Nourianz | $329 | $407,190129 claims |
| MDD US Operations, LLCGocovri | $1,349 | $273,65952 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $559 | $67,23612 claims |
| Acorda Therapeutics, IncInbrija | $169 | $48,71613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.